Although the present study demonstrates the therapeutic potential of C11 utilizing a model of CPVT where the primary pathological mechanism is directly related to β1AR activation, C11 could be applied as a treatment for a wide range of cardiac diseases (i.e., hypertrophic and dilated cardiomyopathy) or arrhythmic disorders (i.e., long QT syndrome, arrhythmogenic cardiomyopathy, atrial fibrillation) that are potentiated by excessive sympathetic stimulation and where beta blockers have been previously shown to be beneficial (7). The gene discussed is ADRB1; the disease is catecholaminergic polymorphic ventricular tachycardia.